Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 17/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231445 | 0.94 | APP (0.49) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3781191 | 0.91 | APP (0.53) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3784276 | 0.91 | APP (0.53) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3771847 | 0.89 | SSTR5 (0.65) | SSTR5HRH1HTR2BACHEKCNH2 | |
| SCHEMBL1748565 | 0.87 | SSTR5 (0.50) | SSTR5HRH1HTR2BACHEKCNH2 | |
| SCHEMBL4231747 | 0.86 | APP (0.49) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL4221954 | 0.86 | APP (0.49) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3787485 | 0.86 | SSTR5 (0.60) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3781106 | 0.86 | SSTR5 (0.66) | APPSSTR5HRH1HTR2BACHE | |
| SCHEMBL3769722 | 0.84 | ACHE (0.55) | APPSSTR5HRH1HTR2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | APP 2063/4885SSTR5 1/4885HRH1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.